Következő fogyasztószerük study-ja buktás, reggeli hír: shares in Novo Nordisk plunged as much as 26% in pre-market trading on Friday as investors reacted to Phase III data for the company's next obesity hopeful CagriSema. While the REDEFINE 1 trial achieved its primary endpoint, weight loss seen with the GLP-1/amylin combination therapy of up to 22.7% fell short of high expectations of around 25%.
